Alongside Amgen Ventures, which was founded in 2004, in Ardelyx's $30m B round were venture capital firms NEA and CMEA and individual investors.

Ardelyx, a US-based healthcare company to treat dietary problems, has raised $30m in its series B round from a consortium including a new investor, Amgen Ventures, the corporate venturing unit of the eponymous drugs maker.

Alongside Amgen Ventures, which was founded in 2004, in the B round were venture capital firms NEA and CMEA and individual investors.

NEA and CMEA had previously invested in Ardelyx’s $26m A round in June 2008, according to data provider VentureDeal.

The B round…